.Pharmacolibrary.Drugs.ATC.A.A10BD14 .Pharmacolibrary.Drugs.ATC.A.A10BD14| name: | MetforminAndRepaglinide |
| ATC code: | A10BD14 | route: | oral |
| n-compartments | 1 |
A fixed-dose combination antidiabetic medication containing metformin and repaglinide. Metformin is a biguanide that decreases hepatic glucose production, while repaglinide is a meglitinide that stimulates insulin secretion from the pancreas. This combination is intended for the treatment of type 2 diabetes mellitus to improve glycemic control, and is currently approved in several countries.
No clinical pharmacokinetic model describing the combination product metformin and repaglinide (A10BD14) in healthy adults or patients has been published to date. Below are estimated pharmacokinetic parameters based on known models for each drug administered orally.
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Abe, M, et al., & Soma, M (2011). Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Current drug metabolism 12(1) 57–69. DOI:10.2174/138920011794520053 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21303332
Plosker, GL, & Figgitt, DP (2004). Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 22(6) 389–411. DOI:10.2165/00019053-200422060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15099124